FFO
NMRA icon

Fortitude Family Office’s Neumora Therapeutics NMRA Stock Holding History

Fortitude Family Office’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$326 Sell
167
-855
-84% -$2.22K ﹤0.01% 1818
2025
Q4 		$1.83K Hold
1,022
– – ﹤0.01% 1214
2025
Q3 		$1.86K Buy
+1,022
New +$1.65K ﹤0.01% 1257

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Fortitude Family Office's NMRA Position: Q1 2026 in Review

Fortitude Family Office reduced its Neumora Therapeutics (NMRA) stake by 84% in Q1 2026, selling an estimated $2.22K and leaving 167 shares worth $326. The position accounts for ﹤0.01% of the portfolio, ranked #1818.

Fortitude Family Office first reported a position in NMRA in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.86K in Q3 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Fortitude Family Office held 167 shares of Neumora Therapeutics worth $326 as of Q1 2026.
  • Fortitude Family Office sold 855 Neumora Therapeutics shares in Q1 2026, an estimated $2.22K.
  • Neumora Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1818 holding.
  • Fortitude Family Office first reported a position in Neumora Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Fortitude Family Office's Neumora Therapeutics position peaked at $1.86K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.